for treatment of a chronic inflammation condition associated with rheumatoid arthritis comprising a therapeutically effective amount of an exogenous agonist for decreasing cellular production of one or more of a hmgn1 protein a lcp 1 protein a prtn3 protein a sec22b protein and a pygl glycogen phosphorylase protein application_number US 201314386597 A description two pro inflammatory cytokines well defined in the pathogenesis of rheumatoid arthritis ra and other chronic inflammatory disorders are tumour necrosis factor alpha tnf u03b1 and interleukin 1 u03b2 il 1 u03b2 these cytokines contribute to complex cellular processes in inflammatory diseases many therapies target these cytokines for controlling inflammation but responses to these therapies are variable among patients an impediment in the development of new therapeutic strategies for chronic inflammatory diseases is the limited understanding of underlying molecular mechanisms induced in the presence of these inflammatory stimuli therefore the objective of this study was to identify newly synthesized nascent proteins induced by tnf u03b1 and il 1 u03b2 we hypothesized that identification of de novo nascent proteins that are induced specifically in the presence of either tnf u03b1 or il 1 u03b2 may help to delineate cellular adaptations in presence of these inflammatory stimuli and lead to the identification of new molecular indicators that could be further developed as therapeutic targets of specific advantage would be identification of common proteins that are actively induced in the presence of both tnf u03b1 and il 1 u03b2 these proteins may serve.